The effectiveness of Cholestimide on dyslipidemia with visceral fat accumulation in patients with type 2 diabetes. A randomized parallel crossover trial

INTERVENTION: Administration of Cholestimide 3g/day add on to statin for the first 24 weeks, then withdrawal of Cholestimide for the next 24 weeks Administration of statin for the first 24 weeks, then add Cholestimide 3g/day for the next 24 weeks CONDITION: Type 2 Diabetes, Dyslipidemia PRIMARY OUTCOME: Visceral fat area SECONDARY OUTCOME: 1. Resting energy expenditure, Respiratory quotient; 2. HbA1c, blood glucose, Insulin secretion; 3.lipid metabolism; 4.oxidative stress INCLUSION CRITERIA: Patients whose body mass index(BMI) is above 25, Visceral fat area is above 100cm2, andHbA1c(NGSP) is above 6.5% Patients who have dyslipidemia and administered by Atorvastatin , Pitavastatin or Rosuvastation at least for 2 months, and LDL‐cholesterol is above 90 mg/dl